Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 10/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770114 | 1.00 | GRIN2B (0.54) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2770111 | 1.00 | GRIN2B (0.54) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL731051 | 0.85 | GRIN2B (0.47) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL731052 | 0.85 | GRIN2B (0.47) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL13162568 | 0.84 | SMN1; SMN2 (0.57) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL13162565 | 0.84 | SMN1; SMN2 (0.57) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL19015604 | 0.84 | SMN1; SMN2 (0.57) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL13161930 | 0.82 | SMN1; SMN2 (0.56) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL1965468 | 0.82 | SMN1; SMN2 (0.55) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL13162569 | 0.82 | SMN1; SMN2 (0.56) | GRIN2BSMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | GRIN2B 2085/4885SMN1; SMN2 3213/4885NPC1 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.